Bone Biologics shares rise 20.09% intraday after extending rhNELL-1 product shelf life to 24 months.

Bone Biologics surged 20.09% intraday after announcing it extended the shelf life of its rhNELL-1 product to 24 months, a critical milestone for commercialization. The update, validated by stability data, follows prior 12- and 18-month milestones and is expected to enhance manufacturing efficiency, supply-chain flexibility, and product readiness. CEO Jeff Frelick emphasized the achievement aligns with the company’s long-term strategy, supporting clinical development and shareholder value creation. Multiple news outlets highlighted the extension as a key operational progress for the orthobiologics developer, reinforcing confidence in its spine fusion market potential. The stock’s sharp intraday rise reflects investor optimism over the milestone’s implications for commercial scalability and reduced operational risks.